急性白血病阿糖胞苷耐药机制的研究进展

Progress of mechanism of cytarabine resistance in acute leukemia

阿糖胞苷是一种脱氧胞苷类似物，主要作用于肿瘤细胞S增殖期，可通过抑制细胞DNA的合成，从而干扰肿瘤细胞增殖、达到治疗目的，在急性自血病（AL）的治疗中发挥重要作用。不同的遗传背景以及药物吸收、代谢和消除的效率，可能导致含阿糖胞苷治疗方案的有效性发生变化，影响AL患者的生存。文章就阿糖胞苷在AL中的耐药机制研究进展进行综述。

f acute leukemia. Cytarabine mainly acts on S proliferation phase of tumor cells. Normally, cytosine inte Cytarabine is an anti-metabolic drug with cytotoxicity, which plays an important role in the treatment ogrates with deoxyribose to form deoxycytidine, which is one of the components of DNA. Cytarabine is a deoxycytidine analogue, which can replace the former to form DNA. Therefore, it inhibits the synthesis of cellular DNA, interferes with the proliferation of tumor cells and achieves the therapeutic purpose, due to the different structure. Different genetic backgrounds and different efficiencies of drug absorption, metabolism and elimination may result in changes in the effectiveness of the drug regimen containing cytarabine, which may affect the survival of patients with acute leukemia. The research progress of drug resistance mechanism of cytarabine in acute leukemia is reviewed and summarized in this paper.